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1123-187 Soluble CD40 Ligand in Pulmonary Arterial 
Hypertension: Possible Pathogenic Role of Interaction 
Between Platelets and Endothelial Cells
Jan K. Damås, Kari Otterdal, Arne Yndestad, Halfdan Aass, Nils Olav Solum, Stig S. 
Frøland, Svein Simonsen, Pål Aukrust, Arne K. Andreassen, Research Institute for 
Internal Medicine, Rikshospitalet, Oslo, Norway, Rikshospitalet, Oslo, Norway
Background: Inflammatory processes seem to be involved in the development and pro-
gression of pulmonary arterial hypertension (PAH). CD40 ligand (L) may induce various
biological responses such as matrix degradation and thrombus formation in several
inflammatory disorders. We hypothesized that CD40L also could be involved in the immu-
nopathogenic mechanisms of PAH.
Methods and Results: By comparing soluble (s) CD40L levels in 32 PAH patients and 8
controls, we found several significant differences: 1) Patients with primary pulmonary
hypertension (n=13) and secondary PAH (n=11) had increased sCD40L levels compar-
ing controls (p<0.05 and p<0.01, respectively). 2) In contrast, sCD40L levels were normal
in patients with chronic thromboembolic pulmonary hypertension (n=8) and in other PAH
patients using warfarin. 3) sCD40L levels were higher in arterial (femoral artery) compar-
ing mixed venous blood (pulmonary artery), suggesting production of CD40L in the pul-
monary vasculature. 4) Platelets from patients with PAH showed higher intracellular
levels, enhanced spontaneous and thrombin-stimulated release of sCD40L comparing
controls (p<0.01). Finally, in vitro studies demonstrated that sCD40L induced chemokine
expression (i.e. MCP-1 and IL-8) in endothelial cells. Indeed, MCP-1 and IL-8 were ele-
vated and correlated to pulmonary vasculature resistance in PAH (p<0.01). Surprisingly,
prostacycline enhanced MCP-1 levels in PAH patients in vivo and in CD40L-stimulated
HUVEC in vitro, suggesting some unfavorable effects of this medication in PAH.
Conclusion: Raised platelet-derived CD40L levels in PAH patients may (i) reflect
enhanced platelet activation and thrombus formation in these patients, and (ii) induce
chemokine expression in endothelial cells. These processes could contribute to the the
pathogenesis of this disorder.
1123-188 Role of Amlodipine in Preventing and Reversing 
Monocrotaline-Induced Pulmonary Arterial 
Hypertension in Rats
Eiichiro Mawatari, Minoru Hongo, Akio Sakai, Ruan Zonghai, Fumiaki Ogiwara, Noboru 
Watanabe, Yuichi Kamiyoshi, Osamu Kinoshita, Keishi Kubo, Shinshu University, 
Matsumoto, Nagano, Japan
Background: Amlodipine has been reported to be beneficial to improve coronary
microvascular endothelial function, inhibit proliferation of vascular smooth muscle cells
and expression of matrix metalloproteinase-1 in vascular endothelial cells, and exert anti-
oxidant actions. The present study was designed to examine the role of amlodipine in
preventing and reversing monocrotaline (MCT)-induced pulmonary arterial hypertension
(PAH) in rats. Methods: Rats were injected with 40 mg/kg of MCT subcutaneously and
randomized to either 6mg/kg/day of amlodipine in drinking water or placebo for 3 weeks.
Animals treated with MCT and survived for 3 weeks were assigned to either amlodipine
(6mg/kg/day) or placebo for next 3 weeks. The animals had measurement of cardiac
weights and pulmonary arterial pressure, and then underwent histologic and Western
blot analyses of the lung tissue after treatment. Results: Amlodipine immediately follow-
ing MCT injection markedly inhibited PAH (mean pulmonary arterial pressure: 32.0 ± 2.9
mmHg in the placebo group vs 16.4 ± 2.1 mmHg in the amlodipine-treated group, p <
0.01) with severe pulmonary vascular remodeling and right-sided heart failure. The sur-
vival rate at 3 weeks after treatment was significantly increased in the amlodipine-treated
group compared with the placebo group (90 % vs 44 %, p < 0.05). eNOS expression in
the lung tissue was significantly reduced in the placebo group, but it was markedly
improved after 3 weeks of amlodipine (p < 0.001). Late treatment with amlodipine did not
palliate PAH nor improved survival. Conclusions: Amlodipine immediately after MCT
injection inhibited development of PAH and improved survival in rats. These effects were
associated with marked upregulation of eNOS in the lung tissue. In contrast, amlodipine
failed to reverse established PAH. Thus, this study may provide an insight into therapeutic
strategy of amlodipine in PAH.
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1124-189 Degree of Physical Activity Is Associated With 
Subclinical Atherosclerosis in Patients Prone to 
Metabolic Syndrome
Milind Y. Desai, Khurram Nasir, Joel B. Braunstein, John A. Rumberger, Matthew J. 
Budoff, Wendy S. Post, Roger S. Blumenthal, Johns Hopkins University, Baltimore, MD
Background: Metabolic syndrome (MS) is a risk factor for the development of subclinical
atherosclerosis (SA). SA and lack of physical activity (PA) predict coronary heart disease,
however, it is not known whether duration and frequency of PA impacts development of
SA in patients prone to develop MS. We assessed the impact of different degrees of PA
on SA in patients with MS. Methods: We studied 779 patients with MS (patients with
overt diabetes were excluded) referred for electron beam tomography. MS was defined
as blood pressure > 130/85 mm Hg, triglycerides > 150 mg/dl, HDL < 40 mg/dl and body
mass index > 30 kg/m2 (subjects meeting > 2 criteria were included). Patients were
divided into 3 groups: 1 (n = 308) = no PA, 2 (n = 189) = PA < 30 minutes > 2 times/week
and 3 (n = 282)= PA > 30 minutes > 2-3 times/week. Abnormal coronary artery calcifica-
tion (ACAC) or significant SA was defined as a calcium score > 75th percentile based on
gender and age. Results: Patients were 67 % males with a mean age of 54 ± 9 years.
ACAC was present in 30 % of Group 1 patients, 28 % of Group 2 patients and 23 % of
Group 3 patients (figure). Patients without PA had 23 % higher relative probability of
ACAC than patients in the highest PA category (p < 0.05), a finding that persisted after
correction for gender. Lesser degree of PA did not significantly reduce the prevalence of
ACAC. Conclusion: Patients who are prone to MS have a higher prevalence of SA in the
presence of little or no PA relative to those who engage in PA at least 30 minutes per ses-
sions, 2 times a week.
1124-190 Inpatient Cardiac Risk Factor Management Program 
Can Promote Therapeutic Lifestyle Change
Joseph I. Miller, III, Michael Craig McDaniel, Laurence Sperling, The Starr Investigators, 
Deborah Wright, Emory Unversity School of Medicine, Atlanta, GA, Emory Heart Center, 
Atlanta, GA
Background: The STARR (Steps to Achieve Risk Reduction) program is a multi-disci-
plined inpatient program designed to improve patient knowledge of cardiac risk factors,
increase AHA/ACC guideline adherence, and promote lifestyle change. With shorter hos-
pitalizations, it is important to use systematic health delivery strategies for quality care.
While clinical goals have been obtained with similar programs, little is published regard-
ing the ability to promote longterm therapeutic lifestyle change (TLC) in the acute setting.
The STARR program addresses diet, exercise, weight loss, tobacco, stress, hyperten-
sion, lipids, and diabetes.
Methods: STARR utilizes a multi-disciplined approach to educate and manage cardiovas-
cular risk in patients admitted to Emory Hospital. The program uses an algorithm based
on clinical trials and AHA/ACC recommendations. Patient education is accomplished with
a multidisciplinary team and reinforced with educational booklets, magnets, stickers, and
patient contracts. Prior to STARR, a control group of 18 patients underwent phone inter-
view 5 months after discharge and answers recorded on a standardized database.
Patients were evaluated separately on their knowledge of risk reduction goals and self-
reported compliance with diet and exercise. Post STARR, 30 patients were followed 5
months after discharge to assess STARR's impact on knowledge and behavioral compli-
ance with risk reduction. Mean score differences were compared with unpaired Student's
t-test.
Results: Five months after discharge, the STARR patients’ knowledge of exercise and
diet goals was 56.7% (95%CI 47.2-66.1%) versus 18.2% (95%CI 9.5-26.9%) in controls
(p value <0.0001). The STARR patients’ exercise and diet compliance was 67% (95%CI
57.5-75.9) versus 43.5% (95% CI 33.2-53.8, p=0.002). In STARR patients, there was a
trend toward improvement in stress, weight, blood pressure, diabetic, and lipid goals.
Conclusion: An acute inpatient multi-disciplinary based program can influence knowl-
edge and compliance regarding TLC in diet and exercise. This benefit is sustained at 5
months and follow up will assess if it is maintained. Long term, STARR should lower car-
diac morbidity and mortality.
1124-191 Predictive Risk Factors for Coronary Events in Renal 
Transplant Patients
Hallvard Holdaas, Bengt Fellstroem, Alan Jardine, Ed Cole, Gudrun Nyberg, Carola 
Gronhagen-Riska, Soren Madsen, Hans-Hellmut Neumayer, Bart Maes, Patrice Ambuhl, 
Anders Olsson, Ingar Holme, Per Fauchald, Terje Pedersen, John Logan, The ALERT 
Study Group, University of Oslo, Oslo, Norway, Uppsala University, Uppsala, Sweden
A number of observational studies have indicated that coronary heart disease is more
common among renal transplant recipients than in the general population. However, in
renal transplant patients the relation between conventional cardiac risk factors and car-
diac events is less clear than in other populations. Renal transplant recipients may also
acquire non-traditional risk factors as a consequence of renal transplantation procedures.
In the ALERT study, 2102 stable renal transplant recipients (total cholesterol 4.0 – 9.0
mmol/l (received fluvastatin (n=1050) or placebo (n=1052) for a median period of 5.1
years. We analysed the role of traditional and non-traditional risk factors in the placebo
arm of the ALERT study (Lancet 2003;361:2024).
Methods. A univariate risk factor analysis to assess the influence of a large set of poten-
tial risk factors for a predefined composite endpoint (Cardiac Death or Non-fatal MI) was
performed. Subsequently a multivariate model building approach was used to determine
